-New prostate CA dx. yearly 240,000 -NeoAdj study "interesting"...destroying micro tumor and decreasing metastatic dz. saving health care dollars and lives -biological patents to a whole system of cancer antigens and billions and billions of potential revenue.
With just postate cancer this is a multibillion dollar per year company with no expiration in drug patent.
No expiration in drug patent!!!
Potential revisions of antigens as research continues give this company LONGEVITY.
That's why I like SVNT now over DNDN. Way way under the radar, new CEO famous for taking Imclone job to sell it out. Like DNDN has drug approved within the past year or so that got a really slow start due to being expensive with reimbursment issues. Until today.
SVNT was trading above $20 when it was on the block for a buyout that fell through. Now at $2.50. Drug starting to ramp up. Will trade above $5 on first flyonwall rumor, then will get taken over for $9-$10 imho.